{"id":17582,"date":"2025-04-01T22:14:48","date_gmt":"2025-04-01T22:14:48","guid":{"rendered":"https:\/\/leyton.com\/uk\/?post_type=case_study&p=17582"},"modified":"2025-04-01T22:21:08","modified_gmt":"2025-04-01T22:21:08","slug":"amprologix","status":"publish","type":"case_study","link":"https:\/\/leyton.com\/uk\/insights\/case-study\/amprologix\/","title":{"rendered":"AMPROLOGIX"},"content":{"rendered":"
\n
\n
\n

About the client<\/h2>\n

Amprologix Limited seeks to develop new antimicrobials to tackle the growing threat of antimicrobial resistance (AMR), which is reported to be one of the biggest threats to global health and food security.

Their work stems from the discovery of their lead compound, Epidermicin on the human skin, and has shown potential to be the first novel class of antimicrobials developed since the 1980s.
<\/p>\n <\/div>\n <\/div>\n

\n <\/div><\/section>\n\n
\n
\n
\n

How will the R&D benefit help the growth of the company?<\/h2>\n

The additional funds can support ongoing research and development efforts, enabling the company to further investigate and refine its lead compound, Epidermicin NI01.
Overall, the cash injection from a successful R&D tax relief claim would help accelerate the growth of Amprologix Limited, positioning it more competitively in the global market for antimicrobial agents and contributing to the fight against antimicrobial resistance.<\/p>\n <\/div>\n <\/div>\n

\n <\/div><\/section>\n\n\n

<\/h2>\n\n\n
\n

<\/span><\/h2>\n
\n
\n format_quote <\/span>\n
“Leyton UK really know their stuff, both technically and from a tax perspective. They helped make a fairly complicated field very simple, handholding me through the nuances and then getting on with the claim. Our initial concerns about the level of commitment and work required were quickly put at ease – minimal commitment was needed. We sat down with their team to discuss our business, and once they understood it, Leyton did the heavy lifting to ensure a very efficient claim. We were very appreciative of the time Leyton took to truly understand the work we do.” <\/h5>\n
\n

\n GORDON BARKER CEO AMPROLOGIX LTD<\/span>\n <\/p>\n <\/div>\n<\/div> <\/div>\n <\/div>\n<\/section>\n\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n\n
\n
\n
\n
\n

Strengthen your claim<\/h2>\n

Our in-house team of highly experienced scientists, engineers, tax consultants and attorneys would love to answer all your questions and help you make the most out of your R&D efforts.\n\n<\/p>\n

    \n
  1. Global experience<\/li>
  2. Maximise your claim<\/li>
  3. Audit support<\/li>
  4. Team of experts<\/li> <\/ol>\n <\/div>\n <\/div>\n
    \n
    \n
    \n
    \n

    Contact our R&D Tax Experts<\/p>\n

    <\/p>\n

    \n
    \n

    <\/p>